Lai Kin Yaw1, James Owen Robinson2, Kwok Ming Ho3. 1. Department of Intensive Care Medicine, Royal Perth Hospital, Perth, WA, Australia. Electronic address: kim.yaw@health.wa.gov.au. 2. Department of Microbiology and Infectious Diseases, Royal Perth Hospital, Perth, WA, Australia; Australian Collaborating Centre for Enterococcus and Staphylococcus Species Typing and Research, School of Biomedical Sciences, Curtin University, Perth, WA, Australia. 3. Department of Intensive Care Medicine, Royal Perth Hospital, Perth, WA, Australia; School of Population Health, University of Western Australia, Perth, WA, Australia.
Abstract
BACKGROUND: Findings from previous studies have suggested that outcomes after meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia are worse than after meticillin-sensitive S. aureus (MSSA) bacteraemia. We assessed whether patients who had MRSA bacteraemia had a higher risk of death and recurrent infections than those who had MSSA bacteraemia. METHODS: For this observational cohort study, we assessed data from the microbiology laboratory database at the Royal Perth Hospital (WA, Australia). Data were for all patients who had an episode of MRSA bacteraemia between July 1, 1997, and June 30, 2007, and, by use of a computer-generated randomisation sequence, a randomly selected subgroup of patients who had an episode of MSSA bacteraemia (patients with one or more set of blood cultures positive for S. aureus). The primary outcomes were survival time and subsequent infection-related hospital readmissions, analysed by Cox proportional hazards regression with adjustment for important prognostic factors. FINDINGS: Of the 583 patients who had an episode of MRSA or MSSA bacteraemia, we used data for the 582 who had complete data linkage: 185 patients who had MRSA bacteraemia and 397 patients who had MSSA bacteraemia. The crude survival time of patients after MRSA bacteraemia was shorter than it was for patients with MSSA bacteraemia (14 months [IQR 1-86] vs 54 months [3-105]; hazard ratio 1·46, 95% CI 1·18-1·79; p=0·01). The adverse association between MRSA and all-cause mortality (0·98, 0·77-1·30; p=0·87) or infection-related mortality (1·22, 0·89-1·69; p=0·22) were not statistically significant after adjustment for important prognostic factors including age, comorbidities, severity of acute illness, metastatic infections, and long-term care facility resident status. After adjustment for these confounding factors, we saw no difference in infection-related hospital readmissions between patients who had MRSA bacteraemia and those who had MSSA bacteraemia (odds ratio 0·95, 95% CI 0·59-1·53; p=0·83). INTERPRETATION: Long-term outcomes after MRSA bacteraemia were worse than those after MSSA bacteraemia through its confounding associations with other prognostic factors. Our findings might have implications for management strategies to control MRSA colonisation. FUNDING: The Medical Research Foundation of Royal Perth Hospital.
BACKGROUND: Findings from previous studies have suggested that outcomes after meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia are worse than after meticillin-sensitive S. aureus (MSSA) bacteraemia. We assessed whether patients who had MRSA bacteraemia had a higher risk of death and recurrent infections than those who had MSSA bacteraemia. METHODS: For this observational cohort study, we assessed data from the microbiology laboratory database at the Royal Perth Hospital (WA, Australia). Data were for all patients who had an episode of MRSA bacteraemia between July 1, 1997, and June 30, 2007, and, by use of a computer-generated randomisation sequence, a randomly selected subgroup of patients who had an episode of MSSA bacteraemia (patients with one or more set of blood cultures positive for S. aureus). The primary outcomes were survival time and subsequent infection-related hospital readmissions, analysed by Cox proportional hazards regression with adjustment for important prognostic factors. FINDINGS: Of the 583 patients who had an episode of MRSA or MSSA bacteraemia, we used data for the 582 who had complete data linkage: 185 patients who had MRSA bacteraemia and 397 patients who had MSSA bacteraemia. The crude survival time of patients after MRSA bacteraemia was shorter than it was for patients with MSSA bacteraemia (14 months [IQR 1-86] vs 54 months [3-105]; hazard ratio 1·46, 95% CI 1·18-1·79; p=0·01). The adverse association between MRSA and all-cause mortality (0·98, 0·77-1·30; p=0·87) or infection-related mortality (1·22, 0·89-1·69; p=0·22) were not statistically significant after adjustment for important prognostic factors including age, comorbidities, severity of acute illness, metastatic infections, and long-term care facility resident status. After adjustment for these confounding factors, we saw no difference in infection-related hospital readmissions between patients who had MRSA bacteraemia and those who had MSSA bacteraemia (odds ratio 0·95, 95% CI 0·59-1·53; p=0·83). INTERPRETATION: Long-term outcomes after MRSA bacteraemia were worse than those after MSSA bacteraemia through its confounding associations with other prognostic factors. Our findings might have implications for management strategies to control MRSA colonisation. FUNDING: The Medical Research Foundation of Royal Perth Hospital.
Authors: D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern Journal: Anaesthesist Date: 2019-10 Impact factor: 1.041
Authors: G E Park; J-H Ko; S Y Cho; Y E Ha; N Y Lee; C-I Kang; D R Chung; J-H Song; K R Peck Journal: Eur J Clin Microbiol Infect Dis Date: 2017-01-11 Impact factor: 3.267
Authors: Eloise D Austin; Sean S Sullivan; Nenad Macesic; Monica Mehta; Benjamin A Miko; Saman Nematollahi; Qiuhu Shi; Franklin D Lowy; Anne-Catrin Uhlemann Journal: Clin Infect Dis Date: 2020-04-10 Impact factor: 9.079
Authors: D Yahav; S Yassin; H Shaked; E Goldberg; J Bishara; M Paul; L Leibovici Journal: Eur J Clin Microbiol Infect Dis Date: 2016-02-12 Impact factor: 3.267
Authors: Rana F Hamdy; Alice J Hsu; Chris Stockmann; Jared A Olson; Matthew Bryan; Adam L Hersh; Pranita D Tamma; Jeffrey S Gerber Journal: Pediatrics Date: 2017-05-05 Impact factor: 7.124
Authors: Basem Ishak; Amir Abdul-Jabbar; Gregory B Moss; Emre Yilmaz; Alexander von Glinski; Sven Frieler; Andreas W Unterberg; Ronan Blecher; Juan Altafulla; Jeffrey Roh; Robert A Hart; Rod J Oskouian; Jens R Chapman Journal: Neurosurg Rev Date: 2020-08-27 Impact factor: 3.042
Authors: S Pollett; S M Baxi; G W Rutherford; S B Doernberg; P Bacchetti; H F Chambers Journal: Antimicrob Agents Chemother Date: 2016-07-22 Impact factor: 5.191
Authors: Carlos Seas; Coralith Garcia; Mauro J Salles; Jaime Labarca; Carlos Luna; Carlos Alvarez-Moreno; Carlos Mejía-Villatoro; Jeannete Zurita; Manuel Guzmán-Blanco; Eduardo Rodríguez-Noriega; Jinnethe Reyes; Cesar A Arias; Cesar Carcamo; Eduardo Gotuzzo Journal: J Antimicrob Chemother Date: 2018-01-01 Impact factor: 5.790
Authors: Jason P Burnham; Jennie H Kwon; Margaret A Olsen; Hilary M Babcock; Marin H Kollef Journal: Infect Control Hosp Epidemiol Date: 2017-12-17 Impact factor: 3.254